ShareGlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering acute coronary syndrome.
This marks a further disappointment for the heart medicine that has previously failed to pass a late-stage trial for patients with well-treated heart disease.
GSK’s President of Pharmaceuticals R&D Patrick Vallance expressed his disappointment with the result of the second phase III study that did not support a regulatory submission.
The company’s statement declared that the drug darapladib did not achieve the desired primary endpoint of a reduction of major coronary events versus placebo when added to standard of care.
13 May 2014
